Marlene P. Freeman, MD, is an expert in women’s reproductive mental health, the editor-in-chief of The Journal of Clinical Psychiatry, and a professor of psychiatry at Harvard Medical School. She provides ideas that are clinically applicable in this 5 Minute Pearls video. As physicians, understanding the nuances of postpartum psychiatric disorders is crucial for effective patient care. Here are the key takeaways from Dr. Freeman’s insights:

Understanding Xylazine: The Rising Challenge in Opioid Crisis Management As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.

Insomnia is often underrecognized and undertreated in primary care settings. A panel of experts convened by Haymarket Medical Education emphasizes the importance of considering comorbid medical and psychiatric illnesses in patients with insomnia and recommends proactive screening and personalized treatment strategies. As a psychiatrist, neurologist, or other sleep disorder professional, you may often be on the front lines of managing insomnia, a condition that is increasingly prevalent yet remains underrecognized in primary care settings. A recent report by a panel of experts provides crucial insights and recommendations to enhance our approach to this pervasive sleep disorder:

Pfizer is lagging behind its peers with Ibrance, but the pharma giant is attempting to unveil the potential of CDK2 inhibitors to overcome CDK4/6 resistance. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer and Blueprint gave presentations on posters about their respective agents, and Incyte, Cyclacel, and a few private biotechs also had clinical trials going on. Although there are some positive signs, the research is still in its very early stages, and it is not apparent whether CDK2 inhibition is a workable monotherapy method.

Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting:

For week of May 28, 2023 Can you “fill in the blanks” with the right answers in this short quiz of what’s been happening recently in medicine?